<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045274</url>
  </required_header>
  <id_info>
    <org_study_id>GAgban</org_study_id>
    <nct_id>NCT05045274</nct_id>
  </id_info>
  <brief_title>The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction</brief_title>
  <official_title>The Effect of Early Administration of Dapagliflozin in ST Elevation Myocardial Infarction Patients Presenting With Left Ventricular Systolic Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      300 STIMI patients with LV systolic dysfunction will be divided into two equal groups (Group&#xD;
      I (Study arm, n=150); will receive dapagliflozin plus conventional therapy and group (II)&#xD;
      Control arm (n=150); will receive conventional therapy only to detect an improvement in the&#xD;
      LVEF by ≥ 5&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      300 STIMI patients with LV systolic dysfunction will be randomly divided into two equal&#xD;
      groups (Group I (Study arm, n=150); will receive&#xD;
&#xD;
        1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT&#xD;
           loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the&#xD;
           ambulance or emergency department upon diagnosis.&#xD;
&#xD;
        2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will&#xD;
           be individualized according to the patient condition.&#xD;
&#xD;
        3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II&#xD;
           receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other&#xD;
           diuretics will be added in case of volume overload.&#xD;
&#xD;
        4. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after&#xD;
           PPCI.&#xD;
&#xD;
      Group (II) Control arm (n=150); will receive&#xD;
&#xD;
        1. Reperfusion therapy: as in study arm&#xD;
&#xD;
        2. Anti-ischemic treatment: as in study arm.&#xD;
&#xD;
        3. Anti-failure treatment: as in study arm. LV echocardiographic analysis for both groups&#xD;
           at baseline and 3 month follow up by 2D Echocardiography to assess: LVEF by simpson&#xD;
           method Diastolic function LV diameter and volume. LA volume index. LV mass index.&#xD;
           Severity of MR.&#xD;
&#xD;
      Laboratory investigation substudy analysis:&#xD;
&#xD;
      50 patients from either group will undergo NT-proBNP at baseline and after 3 month follow up.&#xD;
&#xD;
      Clinical outcomes:&#xD;
&#xD;
      Patients will be followed up in a deducted outpatient clinic for assessment of clinical&#xD;
      outcomes either by phone cell or clinic visits at 3 month.&#xD;
&#xD;
      Patients will be assessed for the following clinical parameters:&#xD;
&#xD;
      I. Composite of CV death and rehospitalization of HF. II. Individual component at composite&#xD;
      end points. III. Reinfarction or readmission for ACS and target lesion revascularization.&#xD;
&#xD;
      Research outcome measures:&#xD;
&#xD;
      a. Primary (main):&#xD;
&#xD;
      1. The improvement in the LVEF (≥ 5%) using biplane simpson method echocardiography.&#xD;
&#xD;
      a. Secondary (subsidiary):&#xD;
&#xD;
        1. Echocardiographic parameters at 3 month follow up.&#xD;
&#xD;
             1. Changes in LV remodeling.&#xD;
&#xD;
             2. Changes in diastolic function&#xD;
&#xD;
             3. Changes in LA volume index.&#xD;
&#xD;
             4. Changes in LV mass index.&#xD;
&#xD;
        2. Laboratory investigations. Changes of the NT-proBNP from baseline to 3 month follow up&#xD;
&#xD;
        3. Clinical outcomes at 3month. I. Composite of CV death and rehospitalization of HF. II.&#xD;
           Individual component at composite end points. III. Reinfarction or readmission for ACS&#xD;
           and target lesion revascularization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic parameter</measure>
    <time_frame>3 month follow up</time_frame>
    <description>The improvement in the LVEF (≥ 5%) using biplane simpson method echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in LV remodeling</measure>
    <time_frame>3 month follow up</time_frame>
    <description>using echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic function</measure>
    <time_frame>3 month follow up</time_frame>
    <description>using mitral Inflow Patterns electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LA volume index</measure>
    <time_frame>3 month follow up</time_frame>
    <description>using by the biplane area-length method from apical 4- and 2-chamber views electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LV mass index.</measure>
    <time_frame>3 month follow up</time_frame>
    <description>using by linear method electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory investigations.</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Changes of the NT-proBNP from baseline to 3 month follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV death and rehospitalization of HF</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Composite of CV death and rehospitalization of HF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual component at composite end points.</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Composite of CV death or rehospitalization of HF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACS</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Reinfarction or readmission for ACS and target lesion revascularization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(a) Dapagliflozin 10 mg once daily within 24 hours after PPCI for 3 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.&#xD;
Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.&#xD;
Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.&#xD;
Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.&#xD;
Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.&#xD;
Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.</description>
    <arm_group_label>dapagliflozin</arm_group_label>
    <other_name>aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally</other_name>
    <other_name>DAPT, SC-anticoagulation, beta blockers, statin</other_name>
    <other_name>Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.&#xD;
Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.&#xD;
Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.</description>
    <arm_group_label>conventional therapy</arm_group_label>
    <other_name>aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally</other_name>
    <other_name>DAPT, SC-anticoagulation, beta blockers, statin</other_name>
    <other_name>Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1st time STEMI within 24 hours undergoing PPCI. (Chest pain &gt; 30 minutes and ST&#xD;
             segment elevation in more than one lead, include the definition of MI with a&#xD;
             reference: Third universal definition of MI. (published at ESC Clinical Practice&#xD;
             Guidelines 2012).&#xD;
&#xD;
          -  LVEF less than 50%.&#xD;
&#xD;
          -  eGFR ≥20 mL/min/1.73 m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 years old.&#xD;
&#xD;
          -  T1D (Type I diabetes mellitus).&#xD;
&#xD;
          -  Hemodynamically unstable.&#xD;
&#xD;
          -  Cardiogenic shock (clinical syndrome of tissue hypoperfusion resulting from cardiac&#xD;
             dysfunction).&#xD;
&#xD;
          -  History of chronic symptomatic HF with a prior hHF within last year&#xD;
&#xD;
          -  Patients on dialysis.&#xD;
&#xD;
          -  Serious hypersensitivity to dapagliflozin (eg, anaphylaxis, angioedema).&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Sever hepatic impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>George William Agban</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

